Some pharmacists in England can now prescribe medicines for acne, migraines, scabies, ear infections, and rhinitis in a major expansion of the Pharmacy First scheme first introduced in 2024. The five ...
Susan Marlin, chief executive of Clinical Trials Ontario, and Invest Ontario's life sciences lead Garrett Tone, say changes ...
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and ...
The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin ...
Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell ...
Now We Must", this year emphasised the urgency and possibility of ending malaria with existing tools, progressive science, ...
Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...
Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then ...
The move reflected a broader shift in the FDA's approach to AI regulation. Although multiple CDER groups had been involved in ...
A second new drug has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week, RemeGen's telitacicept, further raising the hopes of patients with the debilitating autoimmune ...
Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...
Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement its current activities in patient-facing, generative AI (GenAI) agents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results